Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Leases (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Operating Leases data on record, last reported at $7.5 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 5.72% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, down 5.72%, while the annual FY2025 figure was $7.5 million, 5.72% down from the prior year.
  • Operating Leases reached $7.5 million in Q4 2025 per MIRM's latest filing, down from $9.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $10.0 million in Q3 2024 and bottomed at $328000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $3.8 million, with a median of $1.9 million recorded in 2021.
  • The widest YoY moves for Operating Leases: up 1192.06% in 2024, down 68.91% in 2024.
  • A 5-year view of Operating Leases shows it stood at $1.9 million in 2021, then tumbled by 33.95% to $1.3 million in 2022, then plummeted by 50.91% to $617000.0 in 2023, then surged by 1192.06% to $8.0 million in 2024, then fell by 5.72% to $7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $7.5 million in Q4 2025, $9.4 million in Q3 2025, and $10.0 million in Q2 2025.